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1078–5884/00A Randomised Controlled Trial of the Use of a Tourniquet to
Reduce Blood Loss During Transtibial Amputation for
Peripheral Arterial Disease
S.A. Choksy, P. Lee Chong, C. Smith, M. Ireland and J. Beard*Sheffield Vascular Institute, Northern General Hospital, Sheffield S5 7AU, UKObjectives. To examine the effects of an exsanguination tourniquet on blood loss during transtibial amputation in patients
with peripheral arterial disease (PAD).
Design. Prospective randomised blinded controlled trial.
Materials and methods. Sixty-four patients undergoing transtibial amputation for non-reconstructible PAD were
randomised to either tourniquet or no tourniquet (control). Blood loss (primary outcome), fall in haemoglobin, transfusion
requirements, wound healing, breakdown and revision (secondary outcomes) were also recorded.
Results. Twenty-five patients in the tourniquet and 29 in the control group conformed to the trial protocol and completed
the follow up. Intra-operative blood loss (median and IQR) was significantly greater in the control group compared to the
tourniquet group (550 ml (255–1050) vs 255 ml (150–572.5), respectively, pZ0.014, Mann–Whitney). There was a
significantly greater drop in haemoglobin concentration (median and IQR) in the control compared to the tourniquet group
(1.8 g/dl (0–1.2) vs1.0 g/dl (0.6–2.4), pZ0.035, t-test). Transfusion requirements were lower in the tourniquet group (pZ
0.05, Mann–Whitney). The rate of wound healing, breakdown and revision were similar in the tourniquet and control
groups, respectively (59 vs 57%, 0 vs 9%, 14 vs 9%, pZNS).
Conclusions. The use of a tourniquet during transtibial amputation for severe PAD reduces blood loss and need for blood
transfusion.Keywords: Peripheral arterial disease; Critical limb ischaemia; Transtibial amputation; Tourniquet; Blood loss; Randomised
controlled trial.Introduction
Limiting blood loss during operative procedures has
well known clinical benefits1 and cost savings,2
particularly in the sort of frail elderly patients that are
often encountered in vascular practice. Exsanguination
tourniquets have been shown to reduce blood loss
duringvaricosevein surgery, reduce thighbruising and
reduce operative time.3,4 However, data examining the
use of tourniquet in patients with peripheral arterial
disease (PAD) is sparse. The traditional view is that
tourniquets are contraindicated during arterial surgery
because they might cause damage to arteries in the
thigh that are already diseased.
Tourniquets are used routinely by many orthopae-
dic surgeons during knee arthroplasty to reduce blood
loss. Most of these patients are elderly and it is likelying author. Jonathan D. Beard, Sheffield Vascular
thern General Hospital, Sheffield S5 7AU, UK.
: jonathan.d.beard@sth.nhs.uk
0646+ 05 $35.00/0 q 2006 Elsevier Ltd. All rights reserthat at least some will suffer from undiagnosed PAD.
The prevalence of peripheral arterial disease amongst
patients undergoing knee arthroplasty is not certain,
but extrapolation from cross sectional population
surveys indicate that the prevalence of asymptomatic
PAD is 8% in the 55–74 age group.5 A recent study
reported that absent pedal pulses and/or an ABPI!
0.9, in the absence of symptoms of critical ischaemia,
was not associated with detrimental outcome in
patients undergoing knee arthroplasty under a
tourniquet.6
Some surgeons now use an exsanguination tourni-
quet during construction of the distal anastomosis of
infrainguinal bypass grafts as this avoids the need to
clamp the vessels.7–9 There have been no previous
randomised clinical trials of tourniquets during
transtibial amputation, but a prospective non-ran-
domised study has recently shown that the use of a
pneumatic tourniquet significantly reduces fall in
haemoglobin concentration and transfusion require-
ments and is associated with reduced revision rates.10Eur J Vasc Endovasc Surg 31, 646–650 (2006)
doi:10.1016/j.ejvs.2006.03.008, available online at http://www.sciencedirect.com onved.
Tourniquet During Amputation 647The aim of this study was to examine the effects of
use of an exsanguination tourniquet in patients
undergoing transtibial amputation for severe PAD.
The primary outcome measure was operative blood
loss. Secondary outcome measures were transfusion
requirements plus the rates of wound haematoma,
wound breakdown, revision and healing.Fig. 1. Boazul cuff rolled up to thigh prior to transtibial
amputation.Patients and Methods
Ethics approval for the study was granted by the
North Sheffield Research Ethics Committee and full
informed consent was obtained from patients prior to
participation in this study. Patients were considered
for the study if they had severe infrainguinal PAD
(rest pain, ulceration and/or gangrene) that required
transtibial amputation. Previous angiography in all
patients had shown no possibility of revascularisation
or revascularisation had failed to result in healing.
Both diabetics and non-diabetics were included in the
study. Transfemoral amputations were excluded as it
is difficult to apply the tourniquet high enough at this
level. All patients received standard DVT prophylaxis
with low molecular weight heparin. Baseline data on
demography, ABPI, previous attempt at revascularisa-
tion, diabetes, ulceration or gangrene, antiplatelet or
anticoagulant therapy and preoperative haemoglobin
was collected on a standard proforma.
Randomisation was performed using a random
number table and randomisation details were placed
in sealed envelopes which were opened in the
operating theatre just prior to commencing the
operation. Details of operative blood loss and ran-
domisation to tourniquet or not were kept separate
from the patient case notes. Postoperative review at 1
week and 6 weeks was conducted by a vascular
research nurse (CS or MI), who was blinded to the
randomisation process.
Operations were performed under regional anaes-
thesia. The choice of technique (Burgess or skew-flap)
was left to the individual surgeon. All patients,
irrespective of tourniquet use, received preoperative
antibiotics (augmentin 1.2 g and gentamicin 120 mg).
In patients randomised to tourniquet, an autoclavable
Lofquist cuff (Boazal, Sweden), normally used for
varicose vein surgery,4 was rolled up to the thigh to
exsanguinate the leg and to provide a bloodless field,
after prepping the leg, before the skin incision (Fig. 1).
The cuff was removed after division of the tibia and
fibula and fashioning the flaps to the correct length.
This permitted any bleeding from small arteries and
venous sinuses in the muscle to be under run before
closing the flaps in layers with an absorbable suture(Vicryl, Ethicon, UK). The wounds were dressed with
a transparent waterproof dressing (Opsite, Smith and
Nephew, UK) and a 12 F suction drain were used in all
operations.
The amount of intra-operative blood loss was
carefully measured from suction and swabs. Tourni-
quet time was also recorded. Follow up was
performed at 1 week and 6 weeks postoperatively.
Data collected postoperatively included stump com-
plications (wound breakdown or revision), transfusion
requirements, cardio respiratory complications and
death. The postoperative haemoglobin concentration
was also recorded and the patient was given a blood
transfusion if the haemoglobin level fell below 8 g/dl.
To show a difference in blood loss of 30% between
control and tourniquet with test power of 80% and aZ
0.05, we estimated that each group would require 25
patients. Statistical analysis was performed with SPSS
software (SPSS, Chicago, Illinois, USA). Group data is
presented as median (IQR). Mann–Whitney test was
used to compare non-parametric data (operative blood
loss, blood transfusion), t-test used to compare
parametric data (drop in haemoglobin) and Fisher’s
Exact test to compare proportions.Results
Seventy-five patients were considered for the study
and 64 were randomised (30 to tourniquet and 34 to no
tourniquet). Following randomisation, there were
seven protocol violations and in a further three
patients the final follow up data was incomplete due
to patient transfer to another hospital in one case,
follow up in a non-surgical clinic in another and finally
in one case 6-week data was lost. During operation, the
tourniquet could not be applied or was removedEur J Vasc Endovasc Surg Vol 31, June 2006
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Fig. 2. Consort flow diagram.
S. A. Choksy et al.648because the leg was too thin due to wasting of thigh
muscles in four patients and in one patient a decision
to convert the operation to a transfemoral amputation
was made intra-operatively. A consort diagram for the
patients in the trial is shown in Fig. 2. Only patients in
whom a full set of data was available were used for
analysis.
Baseline data for the tourniquet and control groups
is presented in Table 1. Both groupswerewell matchedTable 1. Demographic data for control and tourniquet groups
Control
N 29
Age (median and IQR) 69 (63–77)
Sex (M:F) 25:4
Diabetes 18 (62%)
ABPI* (median and IQR) 0.57 (.42–1.1)
Palpable popliteal pulse 8 (27.5%)
Palpable pedal pulses 0
Failed revascularisation 19 (65%)
Ulceration and/or gangrene 21 (72%)
Antiplatelet therapy 17 (68%)
Sepsis 10 (35%)
Anticoagulant therapy 10 (35%)
Preop. haemoglobin level (g/dl) (median
and IQR)
11.1 (10.15–11.8)
All values are medians (IQR).
* No audible Doppler signal in five patients in each group.
Eur J Vasc Endovasc Surg Vol 31, June 2006for age, sex, previous failed revascularisation, the
presence of ulceration or gangrene, prior antiplatelet
or anticoagulant therapy and preoperative haemo-
globin. There were more patients with diabetes in the
control group and this might explain the higher ABPI
in this group due to calcified tibial arteries. However,
the pedal pulses were impalpable in all patients and
the popliteal pulse palpable in a similar proportion of
patients in each group.
The median (IQR) intra-operative blood loss was
550 ml (255–1050) in the control group and 255 ml
(150–572.5) in the tourniquet group (pZ0.014, Fig. 3).
There was a greater drop in haemoglobin concen-
tration in control compared to the tourniquet group
(1.8 (0–1.2) vs 1.0 (0.6–2.4), pZ0.035, Fig. 4). The
number of patients requiring blood transfusion was 14
(50%) in the control and 8 (33%) in the tourniquet
group.and the amount of blood transfused was greater
in the control group compared to the tourniquet group
(pZ0.047, Fig. 5). The median (IQR) operative time in
the tourniquet group was 75 min (61–93) and 76 min
(59–96) in the control group (pZNS).
Stump complications are also shown in Table 2. The
proportion of patients who had wound breakdown
and the proportion of wounds healed at 6 weeks were
similar in both groups. The proportion of patients
requiring formal operative revision of the amputation
stump was also similar in both groups. In the
tourniquet group one patient required revision to
above knee amputation and the remainder in both
groups simply required further wound debridement
and bone trimming. There were no haematomas in the
control group and one haematoma in the tourniquet
group. One patient had died in each group by one
week follow up. The number of patients dying by 6
weeks of follow up was 6 in the control group and 3 in
the tourniquet group. A similar number of patientsTourniquet
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Fig. 3. Box andwhisker plots of blood loss (ml) in control and
tourniquet groups. Horizontal solid and dashed lines
represents group median and mean, respectively. Box
represents interquartile range and whiskers represent 5th
and 95th percentiles. Dots represent outliers. *pZ0.014
(Mann–Whitney) control vs tourniquet groups.
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Fig. 5. Box and whisker plots of transfusion requirements
(units) in control and tourniquet groups. *pZ0.047 (Mann–
Whitney) control vs tourniquet groups.
Tourniquet During Amputation 649suffered postoperative cardiac complications in the
two groups (Table 2).Discussion
Our results confirm that use of an exsanguination
tourniquet during transtibial amputation significantly
reduces intra-operative blood loss by 50%. It seems
that the previous fears about arterial damage from
tourniquets, is unfounded. All patients in this studyControl Tourniquet
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Fig. 4. Box and whisker plots of drop in haemoglobin (g/dl)
in control and tourniquet groups. *pZ0.035 (t-test) control vs
tourniquet groups.had severe infrainguinal PAD with multilevel occlu-
sions, including the superficial femoral artery. At the
level of the thigh, the tourniquet occludes the
profunda femoris collaterals in the thigh muscles,
and these arteries are rarely diseased.
Bleeding is an important predictor of mortality in
surgery.11 Furthermore, elderly frail patients with
diabetes and other risk factors for atherosclerosis are
less likely to tolerate blood loss and shifts in
haemoglobin levels. It seems likely that a reduction
in blood loss will result in clinical benefits. We did not
observe a difference in morbidity and mortality
between the tourniquet and control groups but the
study was not powered for these outcome measures as
many other factors, other than blood loss, contribute to
morbidity and mortality.
Our results are broadly similar to those reported by
Wolthius et al.10 In their study, blood loss was not
measured directly, but inferred from the drop in
haemoglobin concentration and a reduction in transfu-
sion requirements. We also noted a significantly lower
fall in haemoglobin concentration associated with aTable 2. Postoperative morbidity following transtibial amputation
in the control and tourniquet groups
Control (%) Tourniquet (%) p-Value
Wound breakdown 9 0 NS
Revision of
amputation stump
9 14 NS
Wound healing
at 6 weeks
59 57 NS
Myocardial
infarction
7 4 NS
Cardiac
arrhythmias
10 12 NS
Pulmonary
oedema
3 8 NS
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S. A. Choksy et al.650reduction in transfusion requirements. As regards to
amputation revision rates, Wolthius et al. observed a
beneficial effect on stump revision rate in the
tourniquet group. We did not observe a beneficial
effect, perhaps because our study was smaller and was
not powered to detect a difference in this outcome
measure. Another difference between the two studies
was the type of tourniquet used. Wolthuis et al.10 used
the orthopaedic technique of a non-sterile ‘sausage’
rolled up the leg to exsanguinate it before inflating a
thigh tourniquet above arterial pressure to maintain
a bloodless field, before the leg is prepped. We used a
sterile Boazul cuff. This acts as an exsanguinator, as it
is rolled up the leg after prepping, and then maintains
a bloodless field when it is held in position on the
thigh. The cuff is inflated to 120 mmHg before it is
rolled up the leg and this is supposed to result in a
pressure of greater than 300 mmHg on the thigh.
However, we observed that arterial control was
occasionally not achieved in some patients with
wasted thigh muscles. Therefore, we now inflate the
cuff to a higher pressure of 150 mmHg in patients with
thin legs.
In conclusion, our results confirm that the use of an
exsanguination tourniquet during transtibial amputa-
tion significantly reduces intra-operative blood loss by
50% and reduces transfusion requirements.Acknowledgements
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